Skip to main content
Premium Trial:

Request an Annual Quote

GenoMed Amends Deal with VC Group to Speed up Funding

NEW YORK, July 16 (GenomeWeb News) - GenoMed has amended its deal with venture capital group Pierpoint Investissements, allowing it to obtain up to $21 million in funding more quickly, the company said yesterday.

 

Under the original agreement from March, Pierpoint could exercise 35 million warrants over five years once GenoMed's share price reached $1. Now, Pierpoint can exercise these warrants within a 12-month period, which would result in up to $21 million for GenoMed.

 

If Pierpoint placed all 35 million warrants within a year, it would receive 80 million replacement warrants, but only 40 million if it placed just 20 million warrants.

 

Last week, GenoMed said it plans to be listed on the American Stock Exchange.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.